公开(公告)号：US10689451B2

公开(公告)日：2020-06-23

申请号：US15980411

申请日：2018-05-15

申请人： Novartis AG

发明人： Marta Cosenza ,  Christoph Stark

IPC分类号： A61K39/395 ,  C07K16/28 ,  A61K9/00 ,  A61K47/18 ,  A61K47/26 ,  C07K14/715 ,  A61K39/00

摘要： Anti-BAFFR antibodies are formulated as liquid formulation comprising a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The aqueous pharmaceutical composition may include one or more sugars, a buffering agent, a surfactant, and/or a free amino acid.

公开(公告)号：US20180051092A1

公开(公告)日：2018-02-22

申请号：US15692490

申请日：2017-08-31

申请人： Novartis AG

发明人： Marta COSENZA ,  Christoph Stark

IPC分类号： C07K16/28 ,  A61K9/00 ,  A61K39/395 ,  A61K47/18 ,  A61K47/26

CPC分类号： C07K16/2878 ,  A61K9/0019 ,  A61K39/3955 ,  A61K39/39591 ,  A61K47/183 ,  A61K47/26 ,  A61K2039/505 ,  C07K16/28 ,  C07K2317/41 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76

摘要： Anti-BAFFR antibodies are formulated as liquid formulation comprising a high concentration of the antibody active ingredient for delivery to a patient without high levels of antibody aggregation. The aqueous pharmaceutical composition may include one or more sugars, a buffering agent, a surfactant, and/or a free amino acid.